EVOLUTIONARY GENOMICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.45 USD | -25.00% |
|
-.--% | -.--% |
| 2023 | Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2023 | Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5.882 | 1.47 | 8.823 | 6.47 | 4.117 | 4.659 |
| Enterprise Value (EV) 1 | 4.711 | 1.311 | 8.736 | 8.5 | 7.647 | 7.825 |
| P/E ratio | -7.52 x | -1.1 x | -8.3 x | -3.24 x | -1.34 x | -2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 180 x | 12.8 x | 71.9 x | 518 x | - | - |
| EV / Revenue | 144 x | 11.4 x | 71.2 x | 680 x | - | - |
| EV / EBITDA | -3.74 x | -1.65 x | -11.9 x | -3.44 x | -4.16 x | -7.88 x |
| EV / FCF | -6.78 x | - | - | -6.98 x | -15.2 x | 223 x |
| FCF Yield | -14.8% | - | - | -14.3% | -6.6% | 0.45% |
| Price to Book | 6.1 x | -5.3 x | -6.87 x | -2.11 x | -0.7 x | -0.63 x |
| Nbr of stocks (in thousands) | 5,882 | 5,882 | 5,882 | 5,882 | 5,882 | 6,655 |
| Reference price 2 | 1.000 | 0.2500 | 1.500 | 1.100 | 0.7000 | 0.7000 |
| Announcement Date | 05/03/18 | 01/04/19 | 30/03/20 | 31/03/21 | 22/03/22 | 09/03/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.0327 | 0.1148 | 0.1227 | 0.0125 | - | - |
| EBITDA 1 | -1.26 | -0.7957 | -0.7341 | -2.47 | -1.839 | -0.9928 |
| EBIT 1 | -1.303 | -0.8368 | -0.7748 | -2.88 | -2.878 | -2.014 |
| Operating Margin | -3,984.79% | -728.83% | -631.55% | -23,038.36% | - | - |
| Earnings before Tax (EBT) 1 | -1.07 | -1.099 | -0.7612 | -2.699 | -2.794 | -1.935 |
| Net income 1 | -0.5396 | -1.099 | -0.7931 | -1.712 | -2.794 | -1.935 |
| Net margin | -1,650.71% | -956.87% | -646.48% | -13,695.06% | - | - |
| EPS 2 | -0.1329 | -0.2280 | -0.1806 | -0.3396 | -0.5236 | -0.3500 |
| Free Cash Flow 1 | -0.6952 | - | - | -1.218 | -0.5045 | 0.0351 |
| FCF margin | -2,126.58% | - | - | -9,742.13% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 05/03/18 | 01/04/19 | 30/03/20 | 31/03/21 | 22/03/22 | 09/03/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 2.03 | 3.53 | 3.17 |
| Net Cash position 1 | 1.17 | 0.16 | 0.09 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.8217 x | -1.919 x | -3.19 x |
| Free Cash Flow 1 | -0.7 | - | - | -1.22 | -0.5 | 0.04 |
| ROE (net income / shareholders' equity) | -11.6% | -27.9% | -23.8% | -68.8% | -612% | 161% |
| ROA (Net income/ Total Assets) | -13.8% | -10.7% | -11.2% | -43.7% | -51.9% | -47.6% |
| Assets 1 | 3.911 | 10.28 | 7.068 | 3.916 | 5.378 | 4.062 |
| Book Value Per Share 2 | 0.1600 | -0.0500 | -0.2200 | -0.5200 | -1.010 | -1.120 |
| Cash Flow per Share 2 | 0.1500 | 0.0200 | 0.0100 | 0.0400 | 0.0400 | 0.0900 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 05/03/18 | 01/04/19 | 30/03/20 | 31/03/21 | 22/03/22 | 09/03/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 2.99M | |
| +48.50% | 57.87B | |
| +41.65% | 40.25B | |
| -6.69% | 39.94B | |
| -5.96% | 28.54B | |
| +12.78% | 26.4B | |
| -20.08% | 19.33B | |
| +31.01% | 12.4B | |
| -0.13% | 12.23B | |
| +25.07% | 12.2B |
- Stock Market
- Equities
- FNAM Stock
- Financials Evolutionary Genomics, Inc.